Clinical trials: Urinary System Tumor
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor…
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00002733
- Testing
- aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Carcinoma, Renal Cell
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
There are two primary aims in the study: 1) to determine the tolerability and feasibility of combination hypofractionated radiation therapy and PD-1 inhibition with nivolumab, and 2) to determine the ability of hypofractionated…
- Trial name
- NCT02962804
- Testing
- Nivolumab, Radiation
- Where
- United States
- Sponsor
- University of Kansas Medical Center
Kidney Cancer
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.
- Trial name
- NCT00004880
- Testing
- dendritic cell vaccine therapy, conventional surgery
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Urothelial/Bladder Cancer, Nos
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor…
- Trial name
- NCT03359239
- Testing
- Atezolizumab, PGV001, Poly ICLC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Galsky
Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
This phase I trial tests the safety and side effects of STIL101 for injection and how well it works in treating patients with pancreatic cancer, colorectal cancer (CRC), renal cell cancer (RCC), cervical cancer (CC) and melanoma…
- Conditions
- Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma
- Trial name
- NCT06626256
- Testing
- Aldesleukin, Biopsy, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
This is a single-centre, single-arm, phase 2 study to evaluate the efficacy and safety of anlotinib hydrochloride plus everolimus in patients with advanced non clear renal cell carcinoma as first-line treatment.
- Trial name
- ALTER-UC-001 (NCT05124431)
- Testing
- Anlotinib hydrochloride, everolimus
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Catheter Site Discomfort, Complications
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
The investigators want to evaluate the efficacy of the propofol and sevoflurane for the prevention of catheter-related bladder discomfort.
- Conditions
- Catheter Site Discomfort, Complications, Anesthesia, Urinary Bladder Neoplasms
- Trial name
- NCT02252445
- Testing
- Propofol, Sevoflurane
- Where
- South Korea
- Volunteers
- 82 people
- Sponsor
- Seoul National University Hospital
Clear Cell Renal Cell Carcinoma
A Phase 1 Trial of ADI-270 in ccRCC
This is a Phase 1 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor [CAR] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
- Trial name
- NCT06480565
- Testing
- ADI-270, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Adicet Therapeutics
Bladder Cancer, Cystectomy
Supporting Sexual Recovery in Women With Bladder Cancer
This study looks at how bladder cancer and removing the bladder can affect women's sexual well-being. Bladder cancer can be more serious in women, and treatment like bladder removal can impact how they feel about themselves and…
- Conditions
- Bladder Cancer, Cystectomy, Female Sexual Dysfunction
- Trial name
- SPARC (NCT07091565)
- Testing
- Qualitative interview/Focus group
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- King's College London
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Bladder Cancer
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer
This prospective pilot study will enroll 30 patients with cT2/T3-N0-M0 urothelial carcinoma of the bladder for whom radical cystectomy with pelvic lymph node dissection is planned.
- Trial name
- NCT01655745
- Testing
- FDG PET/MR
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bladder Cancer
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria
The current study aimed to assess the diagnostic performance of novel urine-based DNA hypermethylation of six genes (GATA4, P16, P14, APC, CDH1 and CD99) for UBC detection in patients with hematuria.
- Trial name
- NCT05362539
- Testing
- Cystoscopy, Computed tomography, DNA hypermethylation assay
- Where
- Egypt
- Volunteers
- 246 people
- Sponsor
- Mansoura University
Kidney Cancer
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00003656
- Testing
- recombinant interferon alfa, tretinoin liposome
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Urothelial Carcinoma Bladder, Androgen Receptor Positive
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs…
- Trial name
- TASUC-Neo (NCT05839119)
- Testing
- Degarelix, Gemcitabine/Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brown University
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with…
- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00006251
- Testing
- total-body irradiation, fludarabine phosphate, cyclosporine
- Where
- 2 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Neoplasms
Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors
Surgical treatment of multiple or recurrent renal tumors may be complicated by renal function impairment. Mini-invasive thermotherapy as radiofrequency (RF), induces necrosis of tumoral tissue while sparing normal renal…
- Trial name
- NCT00221728
- Testing
- Radiofrequency, conservative surgery
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Bordeaux
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Metastatic Renal Cell Carcinoma
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
There is no standard treatment in patients with renal cell carcinoma that was previously treated with VEGF targeted therapies and mTOR inhibitors.So investigators conducted a randomized, open-label, multi-center phase II study to…
- Trial name
- NCT02330783
- Testing
- Bevacizumab, Sorafenib
- Where
- 4 sites in China
- Volunteers
- 106 people
- Sponsor
- Peking University Cancer Hospital & Institute
Bladder Carcinoma, Gastric Carcinoma
Patient-Derived Xenografts to Reduce Cancer Health Disparities
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities.
- Conditions
- Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma
- Trial name
- NCT04410302
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of California, Davis
Renal Cell Carcinoma
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is expressed on the cell surface of 95% of clear cell RCC (ccRCC).
- Trial name
- NCT02883153
- Testing
- Zirconium-89 girentuximab PET/CT
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.